跳至主要内容
临床试验/EUCTR2014-002590-10-FR
EUCTR2014-002590-10-FR进行中(未招募)1 期

Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension - BD-HTAP

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)0 个研究点目标入组 18 人开始时间: 2016年3月2日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Idiopathic or heritable PAH patients, clinically stable during the 3 preceding months, non/never smokers, with normal FEV1/VC ratio but FEF75% ? 60% predicted.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3

排除标准

  • 1. Pregnant women
  • 2. Past or current tobacco-smoking history,
  • 3. A spirometric evidence of an obstructive ventilatory defect as defined by a reduced FEV1/VC ratio below the 5th percentile of the predicted value [43],
  • 4. A FEF75% >60% of predicted normal values at spirometry,
  • 5. A TLC below the 5th percentile of the predicted value [43],
  • 6. A body mass index >30 kg.m-2,
  • 7. Use of supplemental oxygen,
  • 8. PAH induced by drugs and toxins,
  • 9. PAH associated with other conditions, including connective tissue diseases, congenital heart diseases, portal hypertension, and HIV infection [42],
  • 10. Chronic thromboembolic pulmonary hypertension [42],
  • 11. Other respiratory, cardiac and other diseases that could contribute to dyspnoea or exercise limitation,
  • 12. Contraindications to clinical exercise testing, such as NYHA functional class IV, syncope and others, as detailed page 28 elsewhere [26, 44].
  • 1.NYHA functional class IV
  • 3.Acute myocardial infarction (3-5 days)
  • 4.Unstable angina
  • 5.Uncontrolled arrhythmias causing symptoms or hemodynamic compromise
  • 6.Uncontrolled heart failure
  • 7.Active endocarditis
  • 8.Acute myocarditis or pericarditis
  • 9.Symptomatic severe aortic stenosis
  • 10.Suspected dissecting aneurysm
  • 11.Acute pulmonary embolus or pulmonary infarction
  • 12.Thrombosis of lower extremities
  • 13.Uncontrolled asthma
  • 14.Pulmonary edema
  • 15.Room air desaturation at rest <85%
  • 16.Respiratory failure
  • 17.Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)
  • 18.Mental impairment leading to inability to cooperate
  • Relative Contraindications to clinical exercise testing:
  • Specific precision for exclusion criteria n°12: Absolute Contraindications to clinical exercise testing:
  • 1. Left main coronary stenosis or its equivalent
  • 2. Moderate stenotic valvular heart disease
  • 3. Severe untreated arterial hypertension at rest (>200 mm Hg systolic, >120 mm Hg diastolic)
  • 4. Tachyarrhythmias or bradyarrhythmias
  • 5. High-degree atrioventricular block
  • 6. Hypertrophic cardiomyopathy
  • 7. Electrolyte abnormalities
  • 8. Orthopedic impairment that compromises exercise performance
  • 13. Specific contraindications (precautions and drug interactions) to the administration of IB or IB+SALB (please refer to section 7).

研究者

相似试验